These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 34423904)

  • 61. Using alcohol intoxication goggles (Fatal Vision® goggles) to detect alcohol related impairment in simulated driving.
    McCartney D; Desbrow B; Irwin C
    Traffic Inj Prev; 2017 Jan; 18(1):19-27. PubMed ID: 27260944
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Repeated and escalating preoperative subanesthetic doses of ketamine for postoperative pain control in patients undergoing tumor resection: a randomized, placebo-controlled, double-blind trial.
    Rakhman E; Shmain D; White I; Ekstein MP; Kollender Y; Chazan S; Dadia S; Bickels J; Amar E; Weinbroum AA
    Clin Ther; 2011 Jul; 33(7):863-73. PubMed ID: 21722959
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial.
    Daly EJ; Trivedi MH; Janik A; Li H; Zhang Y; Li X; Lane R; Lim P; Duca AR; Hough D; Thase ME; Zajecka J; Winokur A; Divacka I; Fagiolini A; Cubala WJ; Bitter I; Blier P; Shelton RC; Molero P; Manji H; Drevets WC; Singh JB
    JAMA Psychiatry; 2019 Sep; 76(9):893-903. PubMed ID: 31166571
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Assessment of Relationship of Ketamine Dose With Magnetic Resonance Spectroscopy of Glx and GABA Responses in Adults With Major Depression: A Randomized Clinical Trial.
    Milak MS; Rashid R; Dong Z; Kegeles LS; Grunebaum MF; Ogden RT; Lin X; Mulhern ST; Suckow RF; Cooper TB; Keilp JG; Mao X; Shungu DC; Mann JJ
    JAMA Netw Open; 2020 Aug; 3(8):e2013211. PubMed ID: 32785636
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Repeated intranasal ketamine for treatment-resistant depression - the way to go? Results from a pilot randomised controlled trial.
    Gálvez V; Li A; Huggins C; Glue P; Martin D; Somogyi AA; Alonzo A; Rodgers A; Mitchell PB; Loo CK
    J Psychopharmacol; 2018 Apr; 32(4):397-407. PubMed ID: 29542371
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam.
    Rickels K; Pollack MH; Feltner DE; Lydiard RB; Zimbroff DL; Bielski RJ; Tobias K; Brock JD; Zornberg GL; Pande AC
    Arch Gen Psychiatry; 2005 Sep; 62(9):1022-30. PubMed ID: 16143734
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Ketamine augmentation for outpatients with treatment-resistant depression: Preliminary evidence for two-step intravenous dose escalation.
    Cusin C; Ionescu DF; Pavone KJ; Akeju O; Cassano P; Taylor N; Eikermann M; Durham K; Swee MB; Chang T; Dording C; Soskin D; Kelley J; Mischoulon D; Brown EN; Fava M
    Aust N Z J Psychiatry; 2017 Jan; 51(1):55-64. PubMed ID: 26893373
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program.
    Doherty T; Wajs E; Melkote R; Miller J; Singh JB; Weber MA
    CNS Drugs; 2020 Mar; 34(3):299-310. PubMed ID: 31994024
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Plasma metabolomic profiling of a ketamine and placebo crossover trial of major depressive disorder and healthy control subjects.
    Moaddel R; Shardell M; Khadeer M; Lovett J; Kadriu B; Ravichandran S; Morris PJ; Yuan P; Thomas CJ; Gould TD; Ferrucci L; Zarate CA
    Psychopharmacology (Berl); 2018 Oct; 235(10):3017-3030. PubMed ID: 30116859
    [TBL] [Abstract][Full Text] [Related]  

  • 70. A Randomized Controlled Trial of Repeated Ketamine Administration for Chronic Posttraumatic Stress Disorder.
    Feder A; Costi S; Rutter SB; Collins AB; Govindarajulu U; Jha MK; Horn SR; Kautz M; Corniquel M; Collins KA; Bevilacqua L; Glasgow AM; Brallier J; Pietrzak RH; Murrough JW; Charney DS
    Am J Psychiatry; 2021 Feb; 178(2):193-202. PubMed ID: 33397139
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Mild to moderate dehydration combined with moderate alcohol consumption has no influence on simulated driving performance.
    Irwin C; Leveritt M; Shum DH; Desbrow B
    Traffic Inj Prev; 2014; 15(6):652-62. PubMed ID: 24867575
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Crossover Study Evaluating the Abuse Potential of the Antiepileptic Drug Lacosamide in Healthy Recreational Drug Users.
    Schoedel KA; Andreas JO; Doty P; Eckhardt K; Sellers EM
    J Clin Psychopharmacol; 2017 Dec; 37(6):675-683. PubMed ID: 28926353
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Effects of Mu-Opiate Receptor Gene Polymorphism rs1799971 (A118G) on the Antidepressant and Dissociation Responses in Esketamine Nasal Spray Clinical Trials.
    Saad Z; Hibar D; Fedgchin M; Popova V; Furey ML; Singh JB; Kolb H; Drevets WC; Chen G
    Int J Neuropsychopharmacol; 2020 Dec; 23(9):549-558. PubMed ID: 32367114
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Default Mode Connectivity in Major Depressive Disorder Measured Up to 10 Days After Ketamine Administration.
    Evans JW; Szczepanik J; Brutsché N; Park LT; Nugent AC; Zarate CA
    Biol Psychiatry; 2018 Oct; 84(8):582-590. PubMed ID: 29580569
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Repeated ketamine infusions for antidepressant-resistant PTSD: Methods of a multicenter, randomized, placebo-controlled clinical trial.
    Abdallah CG; Roache JD; Averill LA; Young-McCaughan S; Martini B; Gueorguieva R; Amoroso T; Southwick SM; Guthmiller K; López-Roca AL; Lautenschlager K; Mintz J; Litz BT; Williamson DE; Keane TM; Peterson AL; Krystal JH;
    Contemp Clin Trials; 2019 Jun; 81():11-18. PubMed ID: 30999057
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Coadministration of nefazodone and benzodiazepines: III. A pharmacokinetic interaction study with alprazolam.
    Greene DS; Salazar DE; Dockens RC; Kroboth P; Barbhaiya RH
    J Clin Psychopharmacol; 1995 Dec; 15(6):399-408. PubMed ID: 8748428
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Habenula Connectivity and Intravenous Ketamine in Treatment-Resistant Depression.
    Rivas-Grajales AM; Salas R; Robinson ME; Qi K; Murrough JW; Mathew SJ
    Int J Neuropsychopharmacol; 2021 May; 24(5):383-391. PubMed ID: 33249434
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Oral ketamine for the rapid treatment of depression and anxiety in patients receiving hospice care.
    Irwin SA; Iglewicz A
    J Palliat Med; 2010 Jul; 13(7):903-8. PubMed ID: 20636166
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Etifoxine versus alprazolam for the treatment of adjustment disorder with anxiety: a randomized controlled trial.
    Stein DJ
    Adv Ther; 2015 Jan; 32(1):57-68. PubMed ID: 25620535
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Evidence that Subanesthetic Doses of Ketamine Cause Sustained Disruptions of NMDA and AMPA-Mediated Frontoparietal Connectivity in Humans.
    Muthukumaraswamy SD; Shaw AD; Jackson LE; Hall J; Moran R; Saxena N
    J Neurosci; 2015 Aug; 35(33):11694-706. PubMed ID: 26290246
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.